Navigation Links
Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria
Date:2/24/2010

of Maryland School of Medicine, in a poster presentation entitled Human Adaptive Immune Response to Bacillus Anthracis.  

Valortim® is a fully human anti-toxin monoclonal antibody being developed for the prevention and treatment of inhalational anthrax.  Preclinical studies suggest that Valortim® has the potential to provide protection against anthrax infection when administered prophylactically (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident).

Previous data presented by Drs. Cross and Basu have shown that in addition to inhibiting anthrax toxin, Valortim® appears to augment the immune system's ability to kill anthrax bacilli by enhancing the human dendritic cell response to a challenge with anthrax spores.  These new data expand upon these observations by showing that Valortim® also enhances the human T cell response to B. anthracis. In addition to Valortim's established toxin-neutralizing function, which has been previously described, these studies indicate that it may also assist in enhancing the adaptive immune response to anthrax, which may lead to a reduction and clearance of the bacteria in the host organism.

Dr. Cross remarked, "Our latest research using human immune cells pr
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
2. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
3. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
4. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
6. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
7. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
8. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
9. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
10. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
11. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Elekta (NSE:EKTAb) and Royal ... Christie NHS Foundation Trust ( Manchester, UK ... whose mission is to develop the clinical value of ... system. Such a system would, in principle, improve the ... "The Christie was an essential participant ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
(Date:7/22/2014)...  Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. ... with the Icahn School of Medicine at ... ) to utilize its proprietary information and data package ... Niemann-Pick Type C Disease (NPC), a rare disease, mostly ... license also covers other diseases and disorders relying on ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
... N.J., Nov. 4 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... months ended September 30, 2009, ending the quarter with $67.5 ... million from December 31, 2008. In October 2009, we ... offering costs from an underwritten public offering of 4,945,000 shares ...
... , PARIS, Nov. 4 Alcatel-Lucent (Euronext Paris and ... TeleHealth Manager, a secure and reliable remote patient monitoring ... Drug Administration (FDA) for marketing in the United States. ... supports remote patient monitoring with an easily deployable ...
Cached Medicine Technology:Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 8Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 9Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 10Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 11Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 12Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 13Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 14U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States 2U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States 3
(Date:7/22/2014)... The European Bio stimulants Market report defines ... analysis and forecast of revenue. The bio stimulants market ... million in 2013 to $940.6 million by 2018, at ... Browse through the TOC of the Europe Bio stimulants ... analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html , Agriculture contributes ...
(Date:7/22/2014)... 22, 2014 Alliance Storage ... data archiving solutions, has announced the availability of ... archiving solution. The unique new solution merges optical ... on compliant data archiving across all industries including ... The introduction of the new archiving tier permits ...
(Date:7/22/2014)... Murcia have studied the changes in the brain ... that causes difficulties in inhibiting a response in ... unplanned actions without considering the negative consequences. These ... the risk of behavioural problems. , A new ... Murcia analyses whether the connectivity of an infant,s ...
(Date:7/22/2014)... 22, 2014 There’s an old adage ... to the new improvements and enhancements Global Eyeglasses has ... to make lasting impressions while having what they need ... great, everyday. , “We are offering new sports clip ... said Arjun Sagar, CEO of Global Eyeglasses . ...
(Date:7/22/2014)... As part of a multinational, collaborative effort, ... Sinai have helped identify over 100 locations in the ... in the largest genomic study published on any psychiatric ... published online in Nature, point to biological mechanisms and ... new approaches to treating the disorder, which has seen ...
Breaking Medicine News(10 mins):Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 2Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 3Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 4Health News:Children's impulsive behaviour is related to their brain connectivity 2Health News:Global Eyeglasses Adds New Products and Enhances Services 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 3Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 4
... there, experts warn , SUNDAY, Sept. 16 (HealthDay News) ... States occur at home but are preventable, according to ... From cleaning products to coat hangers, the average American ... accidents. Americans can take simple steps, such as wearing ...
... Lifestyle Experts - Plus TV Style, Expert ... Patients Through Live ... 15 People suffering from painful and,at times, embarrassing, ... Foundation officially launched the 2007 PATH program,-- Psoriatic Arthritis ...
... trouble, experts say , , SATURDAY, Sept. 15 (HealthDay News) -- ... or severe stomach pain is another matter that could signal ... People with the following symptoms need to see a doctor: ... pain lasting for hours or days; , pain that wakes ...
... 14 Aid provided by,The Prem Rawat Foundation has ... and their families who were victims of the flooding,earlier ... the flooding, caused by cyclones in this area last ... from their homes. The,Prem Rawat Foundation made a grant ...
... Ill., Sept. 14 The Board of,Directors of ... distributor and,supplier of disposable gloves and other products ... announced it would file a,Form 15 on or ... Exchange,Commission to deregister the Company,s common stock and ...
... HOUSTON, Sept. 14 The following is a,Statement by Oscar S. Wyatt, Jr.: "I,ve seen ... any politicians who want to,return those funds received from me, please return them in the form ... ... DeBakey Medical Foundation ...
Cached Medicine News:Health News:Eye Safety Begins at Home 2Health News:Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis 2Health News:Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis 3Health News:The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique 2Health News:AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange 2
The only daily cleaner specially formulated with isopropyl alcohol to help dissolve lipids and oil-based make-up from contact lenses....
Clerz Plus helps retain moisture to relieve dryness and removes protein buildup from your lenses while you wear them for longer wear comfort....
Lens Plus rewetting drops for soft contact lenses....
... Renu Multiplus preservative free lubricating ... moisturize your eyes while you're ... gentle preservative free formula is ... be sensitive to preservatives and ...
Medicine Products: